Detalles de la búsqueda
1.
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
Mod Rheumatol
; 33(4): 668-679, 2023 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35920102
2.
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
Mod Rheumatol
; 33(1): 64-72, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35365828
3.
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).
Mod Rheumatol
; 33(4): 657-667, 2023 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35921235
4.
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.
Rheumatology (Oxford)
; 61(6): 2413-2423, 2022 05 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34498056
5.
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study.
Rheumatology (Oxford)
; 61(12): 4797-4808, 2022 11 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35377447
6.
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
Mod Rheumatol
; 32(1): 59-67, 2022 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33274687
7.
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Mod Rheumatol
; 32(2): 263-272, 2022 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34910188
8.
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
Mod Rheumatol
; 32(2): 273-283, 2022 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34910203
9.
Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials.
Rheumatol Ther
; 10(1): 161-185, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36327094
10.
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
Rheumatol Ther
; 10(1): 53-70, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36209441
11.
Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
Rheumatol Ther
; 10(1): 71-72, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36598735
Resultados
1 -
11
de 11
1
Próxima >
>>